Evidence base

Peer-reviewed publications

CorteX is backed by published, peer-reviewed research across measurement accuracy, fracture prediction and clinical use.

Not all research listed relates to the intended use of CorteX in the United States.

  1. Opportunistic prediction of osteoporosis and fragility fracture risk from forearm radiographs The OFFER1 Study

    Journal of Bone and Mineral Research Plus
    View

  2. IBEX bone health compared with DXA at the distal-third and ultra-distal radius

    BMC Musculoskeletal Disorders
    View

  3. Validation of forearm aBMD measurement in healthy individuals aged 20 to 30

    ECR 2025 Proceedings
    View

  4. Diagnostic utility for assessment of osteoporosis from knee radiographs

    Frontiers in Molecular Biosciences
    View

  5. Forearm BMD predicts fracture independently of FRAX IBEX sponsored research

    Osteoporosis International
    View

  6. Clinical implementation of opportunistic osteoporosis screening from radiographs using IBEX Bone Health (CorteX) within a fracture liaison service Conference poster

    Royal Osteoporosis Society
    View

IBEX Innovations Ltd is a UK medical device company operating an ISO 13485 quality system. CorteX is CE marked under EU MDR and is also sold under the brand name IBEX BH. It is not cleared for clinical use in the United States; an FDA 510(k) is progress.

Contact us
CorteX is CE-marked (UK/EU). Not cleared by the US FDA; 510(k) pending; not available for sale in the United States.